Serum proteomics in cancer diagnosis and management.
Mass spectrometry-based diagnostics has the potential to revolutionize molecular medicine. Using modern mass-spectrometer technologies, clinical tests can be developed that are practical, robust, accurate, and inexpensive. Serum proteomic pattern profiling couples mass spectrometry with adaptive artificial-intelligence-based bioinformatics, which can now be employed to detect pathological states reflected in the serum proteome. With this approach, rapid and cost-effective tests with exquisite clinical sensitivity and specificity are emerging. These tools may dramatically change how disease is detected, monitored, and managed.
Rosenblatt
Kevin P
KP
Laboratory of Pathology, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland 20892, USA. rosenblk@nihexchange2.nih.gov
Bryant-Greenwood
Peter
P
Killian
J Keith
JK
Mehta
Arpita
A
Geho
David
D
Espina
Virginia
V
Petricoin
Emanuel F
EF
Liotta
Lance A
LA
D001798:Blood Proteins / Q000032:analysis / Q000235:genetics*; D019295:Computational Biology; D006801:Humans; D013058:Mass Spectrometry; D009369:Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D040901:Proteomics
D001798:Blood Proteins